首页> 外文OA文献 >PCV83 AN EVALUATION OF THE INCREMENTAL CHANGE IN THE INCIDENCE OF CARDIOVASCULAR EVENTS AND RELATED COSTS WITH THE ADDITION OF FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY

【2h】

PCV83 AN EVALUATION OF THE INCREMENTAL CHANGE IN THE INCIDENCE OF CARDIOVASCULAR EVENTS AND RELATED COSTS WITH THE ADDITION OF FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY

机译：PCV83评价固定剂量烟酸延长释放和辛伐他汀治疗后，心血管事件和相关费用发生率的增加变化

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Balu S; Simko RJ; Burge RT; Cziraky MJ; Quimbo RA;
展开▼
作者单位

展开▼
年度 2008
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy [J] . Peter P Toth, Kamlesh M Thakker, Ping Jiang, Vascular Health and Risk Management . 2012 ,第4期

机译：与阿托伐他汀单药治疗相比，烟酸缓释/辛伐他汀联合治疗对高密度脂蛋白颗粒产生更大的有利变化
2. Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany [J] . Galin V. Michailov, Glenn M. Davies, Karl J. Krobot The European Journal of Health Economics . 2012 ,第3期

机译：在德国未达到胆固醇目标的二级预防患者中，将烟酸缓释剂/持续剂量的辛伐他汀添加到稳定的辛伐他汀中可延长成本效益
3. Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany [J] . MichailovG.V., DaviesG.M., KrobotK.J. The European journal of health economics: HEPAC : health economics in prevention and care . 2012 ,第3期

机译：在德国未达到胆固醇目标的二级预防患者中，将烟酸/拉洛哌特缓释剂与稳定的辛伐他汀剂量相结合的成本效益
4. Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany [O] . Galin V. Michailov, Glenn M. Davies, Karl J. Krobot -1

机译：在德国未达到胆固醇目标的二级预防患者中将烟酸缓释剂/持续剂量的辛伐他汀添加到稳定的辛伐他汀中可延长成本效益
5. PCV81 AN ECONOMIC EVALUATION OF THE ADDITION OF FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY IN TERMS OF OPTIMAL LIPID VALUE ATTAINMENT [O] . Balu S, Simko RJ, Burge RT, 2008

机译：PCV81最佳脂质价值确定条款对固定剂量烟酸延长释放和辛伐他汀治疗对可管理护理配方的经济评价

PCV83 AN EVALUATION OF THE INCREMENTAL CHANGE IN THE INCIDENCE OF CARDIOVASCULAR EVENTS AND RELATED COSTS WITH THE ADDITION OF FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY

著录项

相似文献

相关主题

期刊订阅